AbbVie Inc. (NYSE:ABBV) Shares Sold by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd decreased its position in AbbVie Inc. (NYSE:ABBVFree Report) by 61.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,193 shares of the company’s stock after selling 9,798 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in AbbVie were worth $834,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ABBV. Kalos Management Inc. purchased a new stake in AbbVie during the first quarter worth about $26,000. Boulder Wealth Advisors LLC purchased a new stake in shares of AbbVie during the fourth quarter worth $31,000. Stone House Investment Management LLC purchased a new stake in shares of AbbVie during the first quarter worth $37,000. True Wealth Design LLC purchased a new stake in shares of AbbVie during the fourth quarter worth approximately $39,000. Finally, General Partner Inc. purchased a new stake in shares of AbbVie during the first quarter worth approximately $40,000. Hedge funds and other institutional investors own 67.86% of the company’s stock.

Insider Activity

In other news, CEO Richard A. Gonzalez sold 18,500 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $149.15, for a total value of $2,759,275.00. Following the completion of the transaction, the chief executive officer now owns 625,294 shares in the company, valued at approximately $93,262,600.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABBV shares. Piper Jaffray Companies upped their target price on shares of AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. started coverage on AbbVie in a report on Thursday, August 17th. They set a “strong-buy” rating for the company. HSBC started coverage on shares of AbbVie in a report on Friday, July 14th. They set a “buy” rating and a $167.00 price objective on the stock. Piper Sandler raised their price objective on shares of AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, July 28th. Finally, Credit Suisse Group dropped their price objective on AbbVie from $170.00 to $160.00 in a report on Wednesday, July 12th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to, the company has a consensus rating of “Moderate Buy” and an average price target of $165.79.

Read Our Latest Research Report on ABBV

AbbVie Stock Down 1.0 %

Shares of NYSE:ABBV opened at $152.09 on Friday. The company has a market cap of $268.45 billion, a price-to-earnings ratio of 31.29, a PEG ratio of 2.74 and a beta of 0.58. The firm’s 50-day simple moving average is $146.09 and its 200-day simple moving average is $147.56. The company has a quick ratio of 0.77, a current ratio of 0.89 and a debt-to-equity ratio of 4.33. AbbVie Inc. has a fifty-two week low of $130.96 and a fifty-two week high of $168.11.

AbbVie (NYSE:ABBVGet Free Report) last posted its quarterly earnings results on Thursday, July 27th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.79 by $0.12. The business had revenue of $13.87 billion during the quarter, compared to analysts’ expectations of $13.52 billion. AbbVie had a return on equity of 151.29% and a net margin of 15.50%. As a group, equities research analysts predict that AbbVie Inc. will post 11.03 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a $1.48 dividend. The ex-dividend date is Thursday, October 12th. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.89%. AbbVie’s dividend payout ratio is presently 121.81%.

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Featured Stories

Want to see what other hedge funds are holding ABBV? Visit to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.